Evidence map›Paper›PMID 42497261›Full record

ArticleScience advances2026

Spatially resolved fetal and maternal cell contributions to severe preeclampsia across gestation.

Yara E Sanchez-Corrales, Theodoros Xenakis, Jose J Moreno-Villena, Leysa Forrest, Neil J Sebire, Elizabeth C Rosser, Lucy R Wedderburn, Sergi Castellano, Sara L Hillman

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yara E Sanchez-CorralesGenetics and Genomic Medicine Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK.ORCID 0000-0003-1438-1994
Theodoros XenakisGenetics and Genomic Medicine Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK.ORCID 0000-0003-3682-8873
Jose J Moreno-VillenaGenetics and Genomic Medicine Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK.ORCID 0000-0002-4608-9632
Leysa ForrestGenetics and Genomic Medicine Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK.ORCID 0009-0005-7167-4672
Neil J SebireDepartment of Histopathology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.ORCID 0000-0001-5348-9063
Elizabeth C RosserCentre for Adolescent Rheumatology Versus Arthritis at UCL, UCL Hospitals and GOSH, London, UK.ORCID 0000-0003-4800-4695
Lucy R WedderburnCentre for Adolescent Rheumatology Versus Arthritis at UCL, UCL Hospitals and GOSH, London, UK.
Sergi CastellanoGenetics and Genomic Medicine Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK.
Sara L HillmanUniversity College London Hospitals (UCLH) NHS Foundation Trust, London, UK.ORCID 0000-0003-2971-6865

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The molecular and cellular pathophysiology of preeclampsia remains poorly understood, but it is increasingly clear that in addition to the placenta, other tissues of the fetal-maternal interface advance the disease. Here, we distinguish fetal and maternal contributions to the early and late presentation of severe preeclampsia by interrogating, across time and space, tissues and cell types relevant to the disease. Accounting for gestational age in a third trimester preterm cohort, we find single-cell and spatial molecular signatures of concerted hypoxia, angiogenic imbalance, fibrosis, and aberrant metabolism in the placenta. In addition, we report maternal immune signatures such as mitochondrial dysfunction and interferon signaling extending to the myometrium and chorioamniotic membranes, likely contributing to the systemic inflammation and endothelial dysfunction in the mother, with impaired fetal cell interactions with endothelial cells in the myometrium contributing to it. These tissue- and cell-specific responses are potential targets for therapy, with their prompt consideration in early gestational disease likely beneficial because of its aggravated molecular presentation. Thus, timely intervention during gestation could change the extremely poor prognosis of severe preeclampsia.

Indexed as

FetusPlacentaPre-EclampsiaFemaleGestational AgeHumansMyometriumPregnancy

Identifiers

PMID42497261
PMCPMC13398505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.